| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04915950 Details | 2023-12-22 Interventional | 2 | 13 | APD791 Neoplasm Metast… Raynaud Disease Scleroderma, Di… Scleroderma, Sy… Sclerosis Raynaud's Pheno… | Business decision This study was terminated early due to a business decision that was not due to any safety concerns. The number of participants was smaller than originally planned and only summary statistics were therefore generated for primary and secondary outcome measures. | |||
| NCT04450316 Details | 2023-12-22 Interventional | 2 | - | Naltrexone Cystitis Cystitis, Inter… Somatoform Diso… Syndrome Bladder Pain Sy… Interstitial Cy… | Study temporarily suspended awaiting research personnel to resume recruitment - | |||
| NCT05932667 Details | 2023-12-21 Interventional | 2 | 1 | Fulvestrant Breast Neoplasm… Advanced or Met… | Financial partner providing study drug could no longer support the trial - | |||
| NCT04425629 2020-003690-21 Details | 2023-12-21 Interventional | 3 | 10078 | Casirivimab and… COVID-19 | Emerging SARS-CoV-2 variants impacting susceptibility to study drug Nasal and saliva sample collection was discontinued early in the study because nasopharyngeal samples were determined to be more reliable for quantitative analysis, as such endpoints related to nasal or saliva samples were not analyzed. The Phase 1/2 SAP does not specify any analyses related to nasal and saliva samples collections | |||
| NCT04267939 2018-003930-34 Details | 2023-12-21 Interventional | 1 | 14 | Niraparib Carcinoma, Ovar… Ovarian Neoplas… Advanced Solid … Ovarian Cancer | There was no anticipated benefit of the experimental combination as tested over available
standard therapies; therefore Sponsor has decided to terminate the investigation. - | |||
| NCT03640481 Details | 2023-12-21 Interventional | 2 | 159 | Belumosudil Bronchiolitis O… Graft vs Host D… Chronic Graft-v… | The sponsor has decided to prematurely terminate the study due to the challenges encountered in
recruiting adolescent participants. This decision was made without any safety concerns. - | |||
| NCT00579969 Details | 2023-12-21 Interventional | 2 | 30 | Latanoprost Timolol Glaucoma | Study stopped and data not analyzed - | |||
| NCT03954041 2018-003858-24 Details | 2023-12-20 Interventional | 2 | 92 | Glyburide Brain Contusion Contusions | Early completed due to strategic considerations, not for efficacy or safety reasons. Early termination of trial due to strategic considerations, not for efficacy or safety reasons. | |||
| NCT02603146 Details | 2023-12-20 Interventional | 2 | 144 | Hydroxychloroqu… Arthritis Arthritis, Rheu… Healthy Partici… Rheumatoid Arth… | Enrollment was closed before reaching the target. In the 1st interim analysis after enrollment
closure, the follow up & treatment of active participants were stopped early due to evidence of
futility. Enrollment closed at 144 randomized participants before reaching the target of 200 due to slow participant accrual. The decision was supported by a revised power analysis suggesting sufficient power for the study with reduced numbers assuming a clinically-relevant difference in RA rates between arms (50% risk for placebo & 25% risk for HCQ). In the 1st interim analysis after enrollment closure, the follow up & treatment of the active participants were stopped early due to evidence of futility. | |||
| NCT04714619 Details | 2023-12-19 Interventional | 2 | 2 | Anastrozole Letrozole Breast Neoplasm… Advanced Breast… | Sponsor decision - | |||
| NCT04151563 2018-004283-65 Details | 2023-12-19 Interventional | 1/2 | 0 | Docetaxel Ipilimumab Nivolumab Ramucirumab Carcinoma, Non-… Lung Neoplasms Carcinoma, Non-… | Business objectives have changed - | |||
| NCT03871829 2018-004185-34 Details | 2023-12-19 Interventional | 2 | 88 | BB 1101 Dexamethasone Dexamethasone a… Multiple Myelom… Neoplasms, Plas… | The decision was made to discontinue the 54767414MMY2065 study as the Data Review Committee
recommendation was early stop of the study for futility. - | |||
| NCT02531854 Details | 2023-12-19 Interventional | 2 | 0 | Pemetrexed Carcinoma Carcinoma, Non-… | Study was withdrawn per sponsor decision - | |||
| NCT02153437 Details | 2023-12-19 Interventional | 1 | 7 | Sotalol Atrial Fibrilla… | - - | |||
| NCT05687110 Details | 2023-12-18 Interventional | 1 | - | Novobiocin Neoplasms Metastatic Mali… Unresectable Ma… | Other - FDA Clinical Hold - | |||
| NCT05330884 Details | 2023-12-18 Interventional | 3 | - | BCG Vaccine Latent Tubercul… Tuberculosis Tuberculosis In… | changes in protocol - | |||
| NCT04515329 Details | 2023-12-18 Interventional | 4 | 0 | Cyclosporine Cyclosporins Lubricant Eye D… Dry Eye Syndrom… Keratoconjuncti… Dry Eye | No participants were enrolled. Study never started. - | |||
| NCT04506554 Details | 2023-12-18 Interventional | 2 | - | Nivolumab Urinary Bladder… Muscle-Invasive… | Slot availability - | |||
| NCT04359017 Details | 2023-12-18 Interventional | 4 | 0 | Lidocaine Hematoma Radius Fracture… Lidocaine Pediatrics Radius Fracture… | Sponsoring staff have left institution - | |||
| NCT03794583 Details | 2023-12-18 Interventional | 3 | 41 | Treprostinil Hypertension Hypertension, P… Lung Diseases Lung Diseases, … Pulmonary Disea… Chronic Obstruc… Pulmonary Hyper… | Sponsor's decision Per sponsor decision, the study was terminated early. |